SCHEMBL20767462

SCHEMBL20767462

Cc1ccc(Cn2c(C=Cc3ccc(F)cc3)nc3ccccc32)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 9/20 0.65
▸ TP53 P04637 5/20 0.65
▸ RAB9A P51151 11/20 0.64
▸ ALDH1A1 P00352 10/20 0.64
▸ KDM4E B2RXH2 9/20 0.64
▸ HPGD P15428 8/20 0.64
▸ NPC1 O15118 8/20 0.64
▸ MAPT P10636 8/20 0.64
▸ HTT P42858 6/20 0.64
▸ MEN1 O00255 4/20 0.64
▸ KMT2A Q03164 4/20 0.64
▸ POLB P06746 1/20 0.64
▸ ALOX12 P18054 1/20 0.64
▸ LMNA P02545 6/20 0.63
▸ L3MBTL1 Q9Y468 6/20 0.63
▸ GAA P10253 5/20 0.63
▸ NFKB1 P19838 4/20 0.63
▸ NFKB2 Q00653 4/20 0.63
▸ RELA Q04206 4/20 0.63
▸ GLA P06280 4/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20767461 1.00 SMN1; SMN2 (0.65) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL24120015 0.83 SMN1; SMN2 (0.60) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL16291785 0.81 SMN1; SMN2 (0.64) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL22822636 0.81 ALDH1A1 (0.76) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL22822622 0.79 SMN1; SMN2 (0.69) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL22822870 0.78 SMN1; SMN2 (0.73) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL22822804 0.77 SMN1; SMN2 (0.81) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL28708639 0.77 KCNH2 (0.59) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL29467867 0.77 KCNH2 (0.59) SMN1; SMN2TP53RAB9AALDH1A1KDM4E
SCHEMBL9543194 0.74 HRH1 (0.56) TP53RAB9AKCNH2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371406-B2 Dual acting FKBP12 and FKBP52 inhibitors PLEX PHARMACEUTICALS, INC. (US) 2025-07-29 — — US disclosed
US-12065407-B2 Dual acting FKBP12 and FKBP52 inhibitors PLEX PHARMACEUTICALS, INC. (US) 2024-08-20 — — US disclosed
US-20210395203-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS PLEX PHARMACEUTICALS, INC. 2021-12-23 — — US disclosed
US-20200399219-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS PLEX PHARMACEUTICALS, INC. 2020-12-24 — — US disclosed
EP-3672934-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS Plex Pharmaceuticals, Inc. (US) 2020-07-01 — — EP disclosed
WO-2019040463-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS PLEX PHARMACEUTICALS, INC. (US) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399219-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS FKBP2, FKBP1B, FKBP1A SMN1; SMN2 379/4885TP53 2291/4885RAB9A 1223/4885
US-20210395203-A1 DUAL ACTING FKBP12 AND FKBP52 INHIBITORS FKBP2, FKBP1B, FKBP1A SMN1; SMN2 379/4885TP53 2291/4885RAB9A 1223/4885
US-12065407-B2 Dual acting FKBP12 and FKBP52 inhibitors FKBP2, FKBP1B, FKBP1A SMN1; SMN2 379/4885TP53 2291/4885RAB9A 1223/4885
US-12371406-B2 Dual acting FKBP12 and FKBP52 inhibitors FKBP2, FKBP1B, FKBP1A SMN1; SMN2 379/4885TP53 2291/4885RAB9A 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback